# Cetuximab + Gemox in Biliary Tract Cancer

> **NCT01216345** · PHASE2 · COMPLETED · sponsor: **Association of Research on the Biology of Liver Tumors** · enrollment: 30 (actual)

## Conditions studied

- Unresectable
- Locally Advanced
- Metastatic

## Interventions

- **DRUG:** Cetuximab + Gemcitabine + Oxaliplatin

## Key facts

- **NCT ID:** NCT01216345
- **Lead sponsor:** Association of Research on the Biology of Liver Tumors
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-10
- **Final completion:** 2009-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2010-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01216345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01216345, "Cetuximab + Gemox in Biliary Tract Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01216345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*